Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Sankyo Completes Purchase of Sankyo Parke Davis Stocks from Pfizer
January 29, 2001
- WHO GLs for Allergic Rhinitis Introduced at UCB Symposium
January 29, 2001
- Kuraya Sanseido Aims at Sales of \1.5 Trillion in Next Stage
January 29, 2001
- BI Establishes Virtual Research Institute of Aging
January 29, 2001
- EMA Dissatisfied with FPMAJ Policy Regarding Healthcare Reform
January 29, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
January 29, 2001
- Yoshitomiyakuhin to Increase Market Share for Antipsychotic Drugs
January 29, 2001
- Major Analysts See Matsumotokiyoshi as No. 1 Drugstore Chain Operator
January 29, 2001
- BUSINESS NEWS IN BRIEF
January 29, 2001
- NHI Program Suffers from Ordinary Loss of \119 Bil. in 1999
January 29, 2001
- Tsuruha: Full-year Sales to Total \80.9 Bil.
January 29, 2001
- Fujirebio: Net Loss due to New Retirement Allowance Accounting
January 29, 2001
- Meiji Seika to Strengthen Its Overseas Business Structures: Vice President Ogawa
January 29, 2001
- PAJ President Uehara Stresses Importance of Self-medication
January 29, 2001
- National Burden Rate Can Be Reduced 10% Through Reform: Koseisho Study Team
January 29, 2001
- Council to Study Ways to Supply Drug Information to Public
January 29, 2001
- Jovi to Increase Its Member Stores to 3,000
January 29, 2001
- REGULATORY NEWS IN BRIEF
January 29, 2001
- JIRA Aims at Introducing Medical Devices Law
January 29, 2001
- Clinical Trial Support System Established in 5 Nat'l Univ.
January 29, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…